Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | VDR | P11473 | 9/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523027 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL10820224 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL817082 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL817094 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL10125598 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL4903376 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL4787102 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL14112429 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL814138 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 | |
| SCHEMBL13790311 | 1.00 | CDC25A (0.46) | CDC25ACDC25BCYP19A1VDRHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8058265-B2 | 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090281340-A1 | 1ALPHA-HYDROXY-2-(3'-HYDROXYPROPYLIDENE)-19-NOR-VITAMIN D COMPOUNDS AND METHODS OF MAKING AND TREATMENT THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2009-11-12 | — | — | US | disclosed |
| WO-2008089093-A2 | EFFICIENT PROCESSES FOR PREPARING STEROIDS AND VITAMIN D DERIVATIVES WITH THE UNNATURAL CONFIGURATION AT C20 (20 ALPHA-METHYL) FROM PREGNENOLONE | QUATRX PHARMACEUTICALS COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20070244072-A1 | 1a-Hydroxy-2-(3'-Hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | CYP2R1, CYP24A1, VDR | CDC25A 1501/4885CDC25B 1749/4885CYP19A1 33/4885 |
| US-20070244072-A1 | 1a-Hydroxy-2-(3'-Hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof | CYP24A1, CYP2R1, VDR | CDC25A 3329/4885CDC25B 3238/4885CYP19A1 55/4885 |
| US-20090281340-A1 | 1ALPHA-HYDROXY-2-(3'-HYDROXYPROPYLIDENE)-19-NOR-VITAMIN D COMPOUNDS AND METHODS OF MAKING AND TREATMENT THEREOF | CYP24A1, CYP2R1, VDR | CDC25A 3469/4885CDC25B 3268/4885CYP19A1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.